Schizophrenia
Conditions
Interventions
Placebo group:Placebo
Sponsors
The Third Hospital of Inner Mongolia Autonomous Region
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meets ICD-10 diagnostic criteria for schizophrenia with a duration of at least 2 years; 2. Positive and Negative Symptom Scale (PANSS) total score >= 60 points; 3. Prior to study enrollment, patients must have taken atypical antipsychotic medication for at least 8 weeks with no medication changes within 21 days; 4. Age between 20 and 70 years; 5. Consent to participate in this study and sign an informed consent form; 6. Patients must be conscious and able to cooperate with examinations, questionnaires, and medical history collection independently or with family assistance. 7. Failure to meet any of the above requirements will result in exclusion from the clinical study.
Exclusion criteria
Exclusion criteria: 1. Individuals with other mental disorders such as organic brain disorders or affective disorders; 2. Those with severe physical illnesses or conditions that may interfere with assessment; 3. Individuals with a history of substance abuse or dependence within the past year; 4. Participants who discontinue or arbitrarily adjust the study medication during follow-up; 5. Individuals with a history of severe suicidal ideation; 6. Those with hearing or visual impairments; 7. Concurrent use of laxatives during follow-up, such as polyethylene glycol electrolyte solutions, phenolphthalein tablets, or senna leaf preparations; 8. Patients with chronic digestive system diseases or tumors, such as peptic ulcers, inflammatory bowel disease, or severe liver disease; 9. Patients with allergy to the study drug or experiencing significant gastrointestinal symptoms such as intolerance; 10. Patients with irregular dietary habits or significant changes in diet during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome;Minimum Mental State Examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fecel metagenomics;Fecel metabolomics;Blood biochemistry;Inflammatory factor; | — |
Countries
China
Contacts
Public ContactZhijian Bai
The Third Hospital of Inner Mongolia Autonomous Region
Outcome results
None listed